{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Safety will be evaluated through collection of adverse events. Total number of adverse events that occurred more than 1% of the time during cycles 1, 2, 7, and 8 when Darzalex-Faspro was administered at the infusion center.","groups":[{"description":"Patients receive daratumumab and hyaluronidase-fihj SC over 3-5 minutes in the infusion center on day 1 of cycles 1, 2, 7, and 8 and at home on day 1 of cycles 3, 4, 5, and 6. Cycles repeat every 28 days for 8 cycles in the absence of disease progression or unacceptable toxicity.\n\nDaratumumab and Hyaluronidase-fihj: Given SC\n\nQuestionnaire Administration: Ancillary studies\n\nQuality-of-Life Assessment: Ancillary studies\n\nInterview: Ancillary studies","id":"OG000","title":"Treatment (daratumumab and hyaluronidase-fihj)"}],"paramType":"NUMBER","populationDescription":"All participants who received Darzalex-Faspro during specified cycles.","reportingStatus":"POSTED","timeFrame":"Cycle 1, Cycle 2, Cycle 7, and Cycle 8, days 1-57 and 169-197","title":"Number of Adverse Events During Infusion Center Administration","type":"SECONDARY","unitOfMeasure":"adverse events"}